- Home
- STWD vs NUVL Comparison
STWD vs NUVL Comparison
Compare STWD & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STWD
- NUVL
- Stock Information
- Founded
- STWD 2009
- NUVL 2017
- Country
- STWD United States
- NUVL United States
- Employees
- STWD N/A
- NUVL N/A
- Industry
- STWD Real Estate Investment Trusts
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- STWD Real Estate
- NUVL Health Care
- Exchange
- STWD Nasdaq
- NUVL Nasdaq
- Market Cap
- STWD 6.7B
- NUVL 5.4B
- IPO Year
- STWD 2009
- NUVL 2021
- Fundamental
- Price
- STWD $20.74
- NUVL $80.48
- Analyst Decision
- STWD Buy
- NUVL Strong Buy
- Analyst Count
- STWD 6
- NUVL 10
- Target Price
- STWD $21.83
- NUVL $119.60
- AVG Volume (30 Days)
- STWD 2.4M
- NUVL 582.7K
- Earning Date
- STWD 08-05-2025
- NUVL 08-07-2025
- Dividend Yield
- STWD 9.26%
- NUVL N/A
- EPS Growth
- STWD N/A
- NUVL N/A
- EPS
- STWD 0.93
- NUVL N/A
- Revenue
- STWD $420,478,000.00
- NUVL N/A
- Revenue This Year
- STWD $349.91
- NUVL N/A
- Revenue Next Year
- STWD $4.33
- NUVL N/A
- P/E Ratio
- STWD $22.23
- NUVL N/A
- Revenue Growth
- STWD 7.97
- NUVL N/A
- 52 Week Low
- STWD $16.59
- NUVL $55.54
- 52 Week High
- STWD $21.17
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- STWD 64.30
- NUVL 59.85
- Support Level
- STWD $19.83
- NUVL $76.27
- Resistance Level
- STWD $20.49
- NUVL $80.90
- Average True Range (ATR)
- STWD 0.29
- NUVL 2.55
- MACD
- STWD 0.03
- NUVL 0.19
- Stochastic Oscillator
- STWD 87.50
- NUVL 81.61
About STWD STARWOOD PROPERTY TRUST INC. Starwood Property Trust Inc.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.